Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 191–200, page 20 of 20. Filter these by subject, year and score in the research library →
-
Research summaries · alzhub.org/study/efficacy-and-safety-of-anti-amyloid-monoclonal-antibodies-in-current-37423541
… Aducanumab, Solanezumab and Lecanemab. The results of this study suggest that anti-Aβ mAbs statistically improved cognitive and biomarker outcomes, particularly Aducanumab and Lecanemab. However, while cognitive effects were of …
-
Research summaries · alzhub.org/study/pharmacological-and-clinical-heterogeneity-of-anti-amyloid-monoclonal-42506306
… driven by trials of lecanemab and donanemab, whereas aducanumab demonstrated discordant results across trials and gantenerumab showed no clinically meaningful benefit. Despite statistical significance, the magnitude of the pooled …
-
Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: Two case reports and systematic review of reported casesResearch summary
Research summaries · alzhub.org/study/severe-symptomatic-amyloid-related-imaging-abnormalities-in-alzheimer-41384832
… were associated with lecanemab, 10 with gantenerumab, 6 with donanemab, and 5 with other antibodies. APOE ε4 was present in 62.5%, including 10 ε4/ε4 homozygotes. Baseline MRI showed hemorrhagic markers in 10 cases, including …
-
Research summaries · alzhub.org/study/critical-assessment-of-anti-amyloid-monoclonal-antibodies-effects-in-39468148
… drug, Donanemab and Lecanemab induced the largest benefits. In subgroup analyses by binding affinity, antibodies without binding to monomers were associated with the most favorable effects. Despite statistical significance for …
-
Research summaries · alzhub.org/study/immunotherapies-targeting-amyloid-and-tau-protein-in-alzheimer-s-37812325
… present. Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in the coming months. In this systematic review, we review all Phase 2 and Phase 3 clinical trials conducted in this indication and the …
-
Monoclonal antibodies for treatment Alzheimer`s diseaseResearch summary
Research summaries · alzhub.org/study/monoclonal-antibodies-for-treatment-alzheimer-s-disease-12954b56
… aducanumab, donanemab, lecanemab, semorinemab, remternetug, trontinemab, gantenerumab, and tilavonemab. The reviewed evidence indicates that mAbs can reduce amyloid plaques and tau aggregates, thereby slowing cognitive decline, …
-
Research summaries · alzhub.org/study/comparative-risk-of-amyloid-related-imaging-abnormalities-with-anti-42434897
… by gantenerumab and lecanemab. APOE ε4 carriage significantly elevated ARIA-E (OR 2.28) and ARIA-H (OR 2.07) risk, with a clear gene-dose effect in homozygotes.ConclusionsARIA risk varies substantially across anti-amyloid-β …
-
Research summaries · alzhub.org/study/the-fda-approved-anti-amyloid-monoclonal-antibodies-for-the-treatment-38017568
… accelerated approval for lecanemab on January 22, 2023. We performed this systematic review and meta-analysis to assess the efficacy and safety of FDA-approved anti-amyloid-β (anti-Aβ) monoclonal antibodies (mabs) for the …
-
Research summaries · alzhub.org/study/application-of-meta-analysis-to-evaluate-relationships-among-aria-e-35320578
… aducanumab, donanemab, lecanemab, and gantenerumab are evaluated with meta-analyses. Linear mixed models for repeated measurements for visits and random study effects are applied to analyze amyloid centiloid value reduction from …
-
Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?Research summary
Research summaries · alzhub.org/study/tracking-neuroinflammatory-biomarkers-in-alzheimer-s-disease-a-39080712
… antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Indeed, in our review, …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.